Imlunestrant and abemaciclib for early ER+ breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding two targeted drugs, imlunestrant and abemaciclib, to your usual hormone therapy can lower the chance of your breast cancer coming back. It is for people with early-stage ER+ breast cancer who have no signs of cancer on scans but have tiny amounts of tumor DNA in their blood (called ctDNA).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery for stage I, II, or III breast cancer that is ER-positive and HER2-negative.
- You have no evidence of cancer on physical exam or scans, but a special blood test found tiny amounts of tumor DNA (ctDNA) in the past 6 months.
- You have been on adjuvant hormone therapy (like tamoxifen or an aromatase inhibitor) for at least 2 years and are still taking it.
- You have not had a CDK 4/6 inhibitor in the last 6 months.
- You are 18 or older, with good kidney, liver, and blood counts, and able to swallow pills.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a special PET scan can predict how well the drug abemaciclib works for people with advanced hormone receptor-positive, HER2-negative breast cancer. If you qualify, you would receive abemaciclib and have imaging scans to see if your cancer responds.
This trial studies whether the combination of abemaciclib and elacestrant can slow or shrink ER-positive, HER2-negative breast cancer that has spread to the brain. It is designed for people whose cancer has progressed despite prior hormone (endocrine) treatment.
This early-phase trial tests several combinations of cancer medicines to slow or control ER-positive breast cancer that has returned or progressed. It also checks safety and whether tumor or blood biomarkers can help match the right treatment to the right person.
This trial tests a combination of two drugs (imlunestrant and abemaciclib) given before surgery for a type of breast cancer that is hormone-receptor positive and HER2 negative. The goal is to see if this treatment shrinks the tumor enough to improve surgery outcomes.
This trial tests whether the drug abemaciclib can help women with hormone receptor-positive, HER2-negative breast cancer who still have signs of cancer DNA in their blood after standard treatment. It aims to prevent a future return of the cancer.
This trial tests whether adding a targeted drug (abemaciclib) to standard treatment helps prevent breast cancer from coming back again after a local recurrence in women with HR-positive, HER2-negative breast cancer.
Hear when a new Anatomic Stage I Breast Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.